Cargando…
Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis
Although combination therapy using trimethoprim–sulfamethoxazole (TMP–SMX) plus echinocandins has been reported to reduce the mortality of patients with pneumocystis pneumonia (PCP), it remains unclear whether it is more effective than TMP–SMX monotherapy, the current first-line treatment for this d...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220274/ https://www.ncbi.nlm.nih.gov/pubmed/35740126 http://dx.doi.org/10.3390/antibiotics11060719 |
_version_ | 1784732333004292096 |
---|---|
author | Kato, Hideo Hagihara, Mao Asai, Nobuhiro Umemura, Takumi Shibata, Yuichi Hirai, Jun Yamagishi, Yuka Iwamoto, Takuya Mikamo, Hiroshige |
author_facet | Kato, Hideo Hagihara, Mao Asai, Nobuhiro Umemura, Takumi Shibata, Yuichi Hirai, Jun Yamagishi, Yuka Iwamoto, Takuya Mikamo, Hiroshige |
author_sort | Kato, Hideo |
collection | PubMed |
description | Although combination therapy using trimethoprim–sulfamethoxazole (TMP–SMX) plus echinocandins has been reported to reduce the mortality of patients with pneumocystis pneumonia (PCP), it remains unclear whether it is more effective than TMP–SMX monotherapy, the current first-line treatment for this disease. Hence, we performed a systematic review and meta-analysis to compare the efficacies of these treatment options for PCP. The Scopus, EMBASE, PubMed, CINAHL, and Ichushi databases were searched for studies (up to January 2022) reporting the mortality and positive response rates (fewer clinical symptoms, improved partial pressure of arterial oxygen, and resolution of pneumonitis on chest imaging) of PCP patients receiving monotherapy or combination therapy. Four studies met the inclusion criteria. All four presented mortality data and one had positive response rates. Compared with the monotherapy, the combination therapy resulted in significantly lower mortality and higher positive response rates (mortality: odds ratio (OR) 2.20, 95% confidence interval (CI) 1.46–3.31; positive response rate: OR 2.13, 95%CI 1.41–3.23), suggesting it to be an effective and promising first-line therapy for PCP. However, further safety evaluations are needed to establish this as a fact. |
format | Online Article Text |
id | pubmed-9220274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-92202742022-06-24 Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis Kato, Hideo Hagihara, Mao Asai, Nobuhiro Umemura, Takumi Shibata, Yuichi Hirai, Jun Yamagishi, Yuka Iwamoto, Takuya Mikamo, Hiroshige Antibiotics (Basel) Article Although combination therapy using trimethoprim–sulfamethoxazole (TMP–SMX) plus echinocandins has been reported to reduce the mortality of patients with pneumocystis pneumonia (PCP), it remains unclear whether it is more effective than TMP–SMX monotherapy, the current first-line treatment for this disease. Hence, we performed a systematic review and meta-analysis to compare the efficacies of these treatment options for PCP. The Scopus, EMBASE, PubMed, CINAHL, and Ichushi databases were searched for studies (up to January 2022) reporting the mortality and positive response rates (fewer clinical symptoms, improved partial pressure of arterial oxygen, and resolution of pneumonitis on chest imaging) of PCP patients receiving monotherapy or combination therapy. Four studies met the inclusion criteria. All four presented mortality data and one had positive response rates. Compared with the monotherapy, the combination therapy resulted in significantly lower mortality and higher positive response rates (mortality: odds ratio (OR) 2.20, 95% confidence interval (CI) 1.46–3.31; positive response rate: OR 2.13, 95%CI 1.41–3.23), suggesting it to be an effective and promising first-line therapy for PCP. However, further safety evaluations are needed to establish this as a fact. MDPI 2022-05-26 /pmc/articles/PMC9220274/ /pubmed/35740126 http://dx.doi.org/10.3390/antibiotics11060719 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kato, Hideo Hagihara, Mao Asai, Nobuhiro Umemura, Takumi Shibata, Yuichi Hirai, Jun Yamagishi, Yuka Iwamoto, Takuya Mikamo, Hiroshige Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis |
title | Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis |
title_full | Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis |
title_fullStr | Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis |
title_short | Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis |
title_sort | efficacy of trimethoprim–sulfamethoxazole in combination with an echinocandin as a first-line treatment option for pneumocystis pneumonia: a systematic review and meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9220274/ https://www.ncbi.nlm.nih.gov/pubmed/35740126 http://dx.doi.org/10.3390/antibiotics11060719 |
work_keys_str_mv | AT katohideo efficacyoftrimethoprimsulfamethoxazoleincombinationwithanechinocandinasafirstlinetreatmentoptionforpneumocystispneumoniaasystematicreviewandmetaanalysis AT hagiharamao efficacyoftrimethoprimsulfamethoxazoleincombinationwithanechinocandinasafirstlinetreatmentoptionforpneumocystispneumoniaasystematicreviewandmetaanalysis AT asainobuhiro efficacyoftrimethoprimsulfamethoxazoleincombinationwithanechinocandinasafirstlinetreatmentoptionforpneumocystispneumoniaasystematicreviewandmetaanalysis AT umemuratakumi efficacyoftrimethoprimsulfamethoxazoleincombinationwithanechinocandinasafirstlinetreatmentoptionforpneumocystispneumoniaasystematicreviewandmetaanalysis AT shibatayuichi efficacyoftrimethoprimsulfamethoxazoleincombinationwithanechinocandinasafirstlinetreatmentoptionforpneumocystispneumoniaasystematicreviewandmetaanalysis AT hiraijun efficacyoftrimethoprimsulfamethoxazoleincombinationwithanechinocandinasafirstlinetreatmentoptionforpneumocystispneumoniaasystematicreviewandmetaanalysis AT yamagishiyuka efficacyoftrimethoprimsulfamethoxazoleincombinationwithanechinocandinasafirstlinetreatmentoptionforpneumocystispneumoniaasystematicreviewandmetaanalysis AT iwamototakuya efficacyoftrimethoprimsulfamethoxazoleincombinationwithanechinocandinasafirstlinetreatmentoptionforpneumocystispneumoniaasystematicreviewandmetaanalysis AT mikamohiroshige efficacyoftrimethoprimsulfamethoxazoleincombinationwithanechinocandinasafirstlinetreatmentoptionforpneumocystispneumoniaasystematicreviewandmetaanalysis |